


# Treatment Strategy Overview for EGFR+ NSCLC

時間：民國 109 年 12 月 3 日 (星期四) 18:30~20:10 會議敬備晚餐

地點：台北喜來登飯店 2 樓瑞穗園 (台北市中正區忠孝東路一段 12 號)

時間	題目	演講者	座長
18:30-18:55	Registration		
18:55-19:00	Opening		陳育民理事長 台灣肺癌學會
19:00-19:30 視訊會議	EGFR talks	Dr. Marina Garassino (Italy) Dr. Ernest Nadal (Spain)	
視訊會議【敬請事先報名，謝謝配合。】 報名連結 <a href="https://e.lilly/326a8yf">https://e.lilly/326a8yf</a> 或 掃描 QR code 報名 → 會議報名步驟，請見下頁 視訊會議註冊說明			
19:30-20:00 實體會議	Update current treatment algorithm for EGFR mutant NSCLC	施金元 主任 台大醫院胸腔科	陳育民理事長 台灣肺癌學會
20:00-20:10	Closing Remarks		陳育民理事長 台灣肺癌學會

主辦單位：台灣肺癌學會

協辦單位：台灣禮來股份有限公司

教育積分：台灣肺癌學會、台灣胸腔暨重症加護醫學會、  
台灣臨床腫瘤醫學會、中華民國癌症醫學會、  
社團法人臺灣臨床藥學會 藥師學分  
中華民國護理師護士公會全國聯合會 護理師學分  
中華民國護理師護士公會全國聯合會 專科護理師學分

# 視訊會議註冊說明

日期: 2020年12月3日  
時間: 12:00 PM 中歐時間  
(即 07:00 PM 台灣時間)

## Overview

**Title:** EGFR Talks: Data from RELAY (Ramucirumab/ Erlotinib) in the treatment of EGFR+ NSCLC and patient case discussion - Session 1

**Date:** Thursday, December 03, 2020

**Time:** 12:00 PM Central European Time

**Duration:** 1 hour

## Register Now

[Already Registered?](#)

① 請填中文名字  
② 請填中文姓氏  
③ 請填電子信箱  
獲取會議連結  
④ 請填所在城市  
⑤ 請選所在國家

First Name\*  
Last Name\*  
Email\*  
City\*  
Country\*  
Taiwan

By registering for this meeting, I agree and hereby give my consent for (i) the use of my personal information to receive and obtain relevant information relating to this meeting and (ii) the transfer of my personal information to the third-party partner association (s) for the sole purpose of obtaining continued medical education (CME) academic credit. By registering I accept the Eli Lilly and Company ("Lilly") Privacy Policy. More information on Lilly's privacy practices can be found [here](#). 註冊此次會議，我同意提供來依據 [隱私權政策](#) 以我提供的個人資料接收此會議相關資訊並同意將我提供的個人資料分享給此次會議合作的學會單位驗證學分。註冊此會議即代表我同意的個人資料可依禮來的 [隱私權政策](#) 予以妥慎使用並處理

For Brazil please enter medical ID here

所屬學會(可複選)

台灣肺癌學會(主辦單位)  台灣臨床腫瘤醫學會  
 中華民國癌症醫學會  台灣胸腔暨重症加護醫學會  
 社團法人臺灣臨床藥學會(藥師)  
 中華民國護理師護士公會全國聯合會(護理師/專科護理師)

請依序填入所屬學會會員編號並以逗號分開(例如: 0123, 0456)

\*Denotes required.

REGISTER

You must have Javascript and Cookies enabled to access this webcast. Click [here](#) for Help.

## Summary

During this interactive webinar, Dr. Ernest Nadal and Dr. Marina Garassino will lead a discussion associated to the newest indication of Cyramza in combination with Erlotinib for EGFR + NSCLC patients and its impact in clinical practice followed by a live Q&A session.

**Country Prescriber Information:** Austria, Brazil, Germany Greece, Hong Kong, Korea, Netherlands, Taiwan

This webinar includes comprehensive information on Lilly products and/or devices, with an approved indication in a set group of countries. It is intended for a specific group of Healthcare Professionals (HCP) working on a country within the list, and invitations have been sent by Lilly personnel only to these HCPs. If you have not received the invitation from a Lilly employee, please ask your Lilly contact if the content is approved in your country.

## Speakers



### Dr. Ernest Nadal

Head of the Section of Thoracic Tumors, Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain

Head of the Section of Thoracic Tumors, Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain. He is an assistant Professor at the University of Barcelona, Department of Clinical Sciences, Campus Bellvitge, L'Hospitalet, Barcelona, Spain. He is the principal investigator of the Clinical Research in Solid Tumors (CReST) group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain. He has published more than 50 papers including papers in high impact journals in the field of oncology and cancer biology



### Dr. Marina Garassino

Chief of the Thoracic Oncology Unit  
Istituto Nazionale dei Tumori, Milano

Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milano. As the chief she is responsible for leading the strategy for clinical and translational research in advanced and locally advanced NSCLC, mesothelioma and thymic malignancies. She has contributed to over 160 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, JCO, Annals of Oncology and New England Journal of Medicine. She had several presentations at international congresses including ASCO, ESMO, ECCO and WCLC.

POWERED BY  
ON24

## ⑥ 請點選您所屬學會(可複選)

- 台灣肺癌學會(主辦單位)
- 台灣臨床腫瘤醫學會
- 中華民國癌症醫學會
- 台灣胸腔暨重症加護醫學會
- 社團法人臺灣臨床藥學會(藥師)
- 中華民國護理師護士公會全國聯合會(護理師/專科護理師)

## ⑦ 請依序填入您所屬學會之會員編號並以逗號分開

例如: 0123, 0456

此為您所選  
第1組學會  
會員編號

此為您所選  
第2組學會  
會員編號

## ⑧ 點此完成註冊